BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio Pharma (BBIO) will present additional Phase 3 CALIBRATE evidence on encaleret at the ASBMR annual meeting on October 9–12, 2026.

Rhea-AI Summary

BridgeBio Pharma (BBIO) will present additional Phase 3 CALIBRATE evidence on encaleret at the ASBMR annual meeting on October 9–12, 2026.

The meeting in Boston will include 24-week findings on patient-reported symptoms, treatment experience and bone turnover in autosomal dominant hypocalcemia type 1 (ADH1), a genetic condition affecting calcium regulation. The encaleret oral presentations are scheduled for October 11. Posters will cover baseline symptoms and daily functioning, plus findings from regional family genetic-testing events conducted with the HypoPARAthyroidism Association. Those events evaluated a model offering no-cost testing and counseling to at-risk relatives in their home region. An October 11 poster will address peripheral FGFR1 inhibition at clinically relevant infigratinib exposures and its relationship to observed safety in children with achondroplasia.

Key Figures

Results period: 24 weeks

Results period

24 weeks

CALIBRATE trial findings scheduled for presentation

Previous Clinical trial Reports

1 past event · Latest: Jul 22

Same Type 1 event

1. Jul 22

   NDA acceptance

   24h Move

   +0.3%

   FDA accepted encaleret's NDA; CALIBRATE met primary and key secondary endpoints.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hypocalcemia, patient-reported outcomes, peripheral FGFR1 inhibition, orphan drug designation

4 terms

hypocalcemia medical

"autosomal dominant hypocalcemia type 1 (ADH1)"

Low calcium levels in the blood that can cause muscle cramps, tingling, irregular heartbeat and, in severe cases, seizures or breathing problems; think of calcium like a battery that helps nerves and muscles run, and when it’s low the body’s systems can falter. Investors care because hypocalcemia can affect clinical trial outcomes, drug safety labels, hospital admissions and treatment markets, influence regulatory reviews and liability risk, and therefore alter a healthcare company’s revenue and valuation.

patient-reported outcomes medical

"effects of encaleret on patient-reported outcomes and on bone turnover"

Reports provided directly by patients about their symptoms, daily functioning, and quality of life—collected through surveys, apps, or interviews—reflecting how a treatment affects real people rather than lab measures. Investors care because these firsthand accounts help regulators, doctors and payers judge a product’s real-world value and can influence approval, pricing, adoption and long-term sales; think of them as customer reviews that show whether a medical product truly improves everyday life.

peripheral FGFR1 inhibition technical

"data showing a lack of peripheral FGFR1 inhibition"

Inhibition of fibroblast growth factor receptor 1 (FGFR1) located in peripheral tissues — achieved by a drug or biologic that blocks FGFR1’s activity outside the central nervous system. FGFR1 is a cell-surface receptor tyrosine kinase that mediates signaling from fibroblast growth factors; blocking it reduces those downstream signals in organs and tissues such as liver, adipose, muscle, and tumors. The phrase “peripheral” distinguishes agents that do not meaningfully act in the brain or spinal cord (for example because they do not cross the blood–brain barrier or are formulated to remain outside the CNS), so effects and side‑effect profiles reflect peripheral FGFR1 blockade rather than central nervous system modulation.

orphan drug designation regulatory

"Fast Track Designation by the U.S. FDA and Orphan Drug Designation"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.

BridgeBio will present the effects of encaleret on patient-reported outcomes and on bone turnover from the Phase 3 CALIBRATE trial. In partnership with the HypoPARAthyroidism Association, BridgeBio will also share findings from regional family cascade genetic testing events that evaluated a proband-initiated model designed to bring no-cost genetic testing and counseling directly to at-risk relatives in their home region.

BridgeBio will also have a poster featuring data showing a lack of peripheral FGFR1 inhibition at clinically relevant infigratinib exposures, supporting the safety profile observed in children with achondroplasia in the PROPEL clinical program.

ADH1 Oral Presentations:
Encaleret Restores Mineral Homeostasis and Increases Bone Turnover in Autosomal Dominant Hypocalcemia Type 1 (ADH1): 24-Week Results from Phase 3 CALIBRATE Trial
Presenter: Erik A. Imel, M.D., Indiana University School of Medicine
Date: Sunday, October 11 at 11:42 am EDT

Participant-Reported Changes in Symptoms and Treatment Experience with Encaleret in Autosomal Dominant Hypocalcemia Type 1: 24-Week Findings from the Phase 3 CALIBRATE Trial
Presenter: Steven W. Ing, M.D., Ohio State University Wexner Medical Center
Date: Sunday, October 11 at 11:54 am EDT

ADH1 Posters:
Baseline Symptom Burden and Impact on Daily Functioning in Autosomal Dominant Hypocalcemia Type 1: Exit Interview Findings from the Phase 3 CALIBRATE Trial
Presenter: Susan Martin, MSPH, RTI Health Solutions
Date: Saturday, October 10 at 2:00 pm EDT

Family Cascade Genetic Testing for Autosomal Dominant Hypocalcemia Type 1: A Multi-Stakeholder Regional Event Model
Presenter: Mark Warren, M.D., Physicians East, Greenville, NC
Date: Saturday, October 10 at 2:00 pm EDT

Achondroplasia Poster:
Lack of Peripheral FGFR1 Inhibition at Clinically Relevant Infigratinib Exposures Supports the Safety Profile Observed in Children with Achondroplasia
Presenter: Bhavik Shah, BridgeBio Skeletal Dysplasias
Date: Sunday, October 11 at 2:00 pm EDT

About Autosomal Dominant Hypocalcemia Type 1 (ADH1)
ADH1 is a common form of genetic hypoparathyroidism caused by gain-of-function variants in the calcium-sensing receptor gene (CASR). The calcium-sensing receptor (CaSR) constantly monitors and balances blood calcium levels by regulating parathyroid hormone secretion and calcium reabsorption in the kidneys. Individuals with ADH1 typically experience hypocalcemia, hypercalciuria, and inappropriately low levels of PTH. Symptoms of hypocalcemia may include severe muscle cramps, muscle spasms (tetany), a burning or prickling sensation in the hands or feet (paresthesia), brain fog, fatigue, and seizures. Hypercalciuria may result in kidney calcification (nephrocalcinosis), kidney stones (nephrolithiasis), and kidney failure.

About Encaleret
Encaleret is an investigational, orally administered small molecule under investigation to treat ADH1 and chronic hypoparathyroidism that is designed to selectively negatively modulate the calcium-sensing receptor. Encaleret has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation in the U.S., European Union, and Japan.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com